



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

May 3, 2018

Anders Blom
Executive Vice President and Interim Chief Financial Officer
Oasmia Pharmaceutical AB
Vallongatan 1
752 28 Uppsala, Sweden

Re: Oasmia Pharmaceutical AB
Form 20-F for the Fiscal Year Ended April 30, 2017
Filed August 24, 2017
File No. 001-37604

Dear Mr. Blom:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Division of Corporation Finance
Office of Healthcare & Insurance